Why is aging the largest risk for developing so many apparently disparate diseases, ranging from neurodegeneration to cancer? One answer to this question lies in the evolutionarily selected, stress-responsive state termed cellular senescence. Senescent cells cease proliferation, which prevents early life cancer. They also secrete numerous molecules that promote tissue repair and regeneration. However, because senescent cells gradually accumulate with age, they eventually cause tissue degeneration, chronic inflammation, and many age-related diseases, including, ironically, late life cancer.
The Campisi lab studies the regulation and characteristics of cell states, with an emphasis on cellular senescence. We use simple and complex human and mouse cell cultures, intact human and mouse tissues, and mouse models to understand the molecular pathways that drive cellular senescence and other cell states. We also use genetic and pharmacological manipulations to understand how cell states cause both the degenerative diseases of aging as well as cancer and to design strategies to modulate or ameliorate their effects.
Why it matters
Aging is a complex, multisystem process that exacts an enormous emotional and economic toll on societies. Understanding and manipulating this process is the next big challenge in biomedical research. It is now clear that many age-related changes and pathologies are caused by cellular responses to endogenous and environmental stimuli. Understanding these responses is essential to developing safe interventions that can extend the years of healthy life in human populations.
Modern medicine has enabled us to extend lifespan - often at the expense of healthspan. My lab is focused on disrupting one of the major drivers of aging. Our goal is to enable more healthy years of life.
Judy Campisi, PhD
Dr. Campisi received a PhD in biochemistry from the State University of New York at Stony Brook and completed her postdoctoral training in cell cycle regulation at the Dana-Farber Cancer Institute and Harvard Medical School. As an assistant and associate professor at the Boston University Medical School, she studied the role of cellular senescence in suppressing cancer and soon became convinced that senescent cells also contributed to aging. She joined the Lawrence Berkeley National Laboratory as a senior scientist in 1991. In 2002, she started a second laboratory at the Buck Institute. At both institutions, Dr. Campisi established a broad program to understand the relationship between aging and age-related disease, with an emphasis on the interface between cancer and aging.
Dr. Campisi is a member of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science.
She has received numerous awards for her research, including two MERIT awards from the National Institute on Aging and awards from the AlliedSignal Corporation, Gerontological Society of America, and American Federation for Aging Research. She is a recipient of the Longevity prize from the IPSEN Foundation, the Bennett Cohen award from the University of Michigan, and the Schober award from Halle University, and she is the first recipient of the international Olav Thon Foundation prize in Natural Sciences and Medicine. Dr. Campisi currently serves on advisory committees for the Alliance for Aging Research, Progeria Research Foundation, and NIA’s Intervention Testing Program. She is also an editorial board member for more than a dozen peer-reviewed journals. Dr. Campisi is a scientific founder of Unity Biotechnology, a California-based company focused on developing therapies for age-related pathologies. She has served on the scientific advisory boards of the Geron Corporation, Sierra BioScience, and Sangamo Biosciences.
Serban Ciotlos PhD Candidate, USC-Buck Biology of Aging Program
Serban completed his B.S. in Bioengineering at the University of California, Santa Cruz, in 2011. From 2012 to 2013, he worked in systems and software engineering at Roche Molecular Systems, and from 2013 to 2017, he worked in bioinformatics at Complete Genomics. His research focuses on investigating the role of senescence in cardiovascular disease, using single cell profiling techniques.
Karen Davis , MD Visiting scientist
Dr. Davis had a career as an anesthesiologist and general medicine practitioner in the community. At present, she is interested in mechanisms of inflammation and aging. She has a particular interest in the degenerative disease sporadic inclusion body myositis as well as sarcopenia associated with aging. Karen Davis is an Independent Visiting Scientist
Pierre-Yves Desprez, PhD Senior Staff Scientist, Scientific Consultant
Dr. Pierre-Yves Desprez first joined the Berkeley National Laboratory after completion of his doctoral thesis at the University of Lyon in France. Dr. Desprez has been a Principal Investigator at the California Pacific Medical Center Research Institute in San Francisco since 1996. The Desprez laboratory is focused on helix-loop-helix transcriptional regulators, their role in regulating cancer progression, as well as on the effects of non-psychotropic cannabinoid compounds to control their expression. As part as the CPMC Precision Medicine Project, Dr. Desprez leads DNA/RNA sequencing and molecular profiling efforts, and, at the Buck Institute, he is a consulting scientist for the Campisi laboratory.
Brendan Hughes Research Associate
Brendan received his B.S. in biological sciences from Cal Poly, San Luis Obispo in December 2020. After an internship at Rubedo Life Sciences in 2019, Brendan discovered his passion for the biology of aging and is excited to continue research in this field in the Campisi lab as a lab manager and research associate.
Koji Kitazawa, MD, PhD Visiting Scientist
Dr. Kitazawa completed medical school and received a PhD in medicine from Kyoto Prefectural University of Medicine, Japan. During his PhD student, he studied the cellular reprogramming of corneal epithelial cells at Center for iPS Research and Application (CiRA), Kyoto University. He specializes in ophthalmology, and his research focus is cellular senescence in the eye, and he is currently investigating the way to keep more healthy years of the eye longer in the Campisi lab. Dr. Kitazawa is visiting from Kyoto University
Chisaka Kuehnemann PhD Candidate, USC-Buck Biology of Aging Program
Chisaka is a PhD candidate in the Buck-USC graduate program, where she is studying cellular senescence, a basic aging process. Prior to joining the Buck, she did oncology drug discovery at Human Genome Sciences. She received a bachelor’s degree from the University of Maryland Baltimore County and a master’s degree from Johns Hopkins University. Her particular research focus is in understanding how certain drugs, such as those used in anti-retroviral therapies, might promote aging by inducing cellular senescence, especially since these drugs have been shown to accelerate aging in human patients. Outside of the lab, she reads science fiction, designs costumes, and is an avid cook.
Pacome Lecot, PhD Postdoctoral Research Fellow
Pacôme received his PhD in immuno-oncology from Claude Bernard University in France. His PhD work focused on the characterization of neutrophil-platelet aggregates in cancer patients’ blood using scRNAseq and imaging flow cytometry. Pacôme then joined the Campisi lab in 2020 as a post-doctoral fellow to decipher mechanism(s) that drive the heterogeneity of senescence programs.
Francesco Neri Pre-doctoral Fellow
Francesco received his B.S. in biotechnology at the University of Bologna (Italy) in 2017 and then completed his M.S. in pharmaceutical biotechnology at the University of Bologna (Italy) in 2019. He joined the Campisi lab in 2019 where he works on cellular senescence and senescence-associated exosomes.
Kohsaku Numa Visiting Scientist
Dr. Numa completed medical school and received a PhD in medicine from Kyoto Prefectural University of Medicine (KPUM), Japan. He specialized in ophthalmology. As a PhD student he student the cellular metabolism of human corneal endothelial cells. In the Campisi lab he is investigating ways to extend the healthspan of the eyes.
Corey Webster, PhD Postdoctoral Fellow
Dr. Webster completed his PhD in molecular cell Bology at UC Berkeley where he characterized the role of an endogenous steroid precursor and its receptor on synaptic function in the developing retina. Prior to this, Corey obtained his BS at UCLA in neuroscience. He then obtained his MSc at San Francisco State while conducting research at UCSF on the molecular pathways of microglia, the brain’s resident immune cell, in the context of cerebral ischemia, as well as the means to mitigate inflammation via mild hypothermia or FDA approved drugs. Corey is currently working on building better molecular tools for the purpose of understanding the aging process, in particular, the signaling between senescent cells of a specific type and their neighbors, as well as how senescent cells can induce damage in neighboring non-senescent cells. When he's not imaging fluorophores, you can find Corey running in the trails, bouldering, or backpacking in one of the amazing National Parks.
Wiley CD, Sharma R, Davis SS, Lopez-Dominguez JA, Mitchell KP, Wiley S, Alimirah F, Kim DE, Payne T, Rosko A, Aimontche E, Deshpande SM, Neri F, Kuehnemann C, Demaria M, Ramanathan A, Campisi J. 2021. Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis. Cell Metab 33:1124-1136.
Dimri, G., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens ,M., Rubelj, I., Pereira-Smith, O., Peacocke, M., Campisi, J. (1195 Sep 26). A novel biomarker identifies senescent human cells in culture and aging skin in vivo. Proc Natl Acad Sci USA, 92(20), 9363–67.
- Krtolica, A., Parrinello, S., Lockett, S., Desprez, P., Campisi, J. (2001 Oct 9). Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc Natl Acad Sci USA, 98(21), 12072–77.
- Coppe, J. P., Patil, C. K., Rodier, F., Sun, Y., Munoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P. Y., Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell non-autonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol, 6(12), 2853–68.
- Rodier, F., Coppe, J. P., Patil, C. K., Hoeijmakers, W. A. M., Munoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., Campisi, J. (2009 Aug). Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion. Nature Cell Biol, 11(8), 973–79.
- Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R. M., Vijg, J., van Steeg, H., Dolle, M. E., Hoeijmakers, J. H., de Bruin, A., Hara, E., Campisi, J. (2014 Dec 22). An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell, 31(6), 722–33.
- Laberge, R. M., Sun, Y., Orjalo, A. V., Patil, P. K., Freund, A., Zhou L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., Limbad, C., Demaria, M., Li P., Hubbard, G. B., Ikeno, Y., Javors, M., Desprez, P. Y., Benz, C. C., Kapahi, P., Nelson, P. S., Campisi, J. (2015 Aug). mTOR regulates the tumor-promoting senescence secretory phenotype by promoting IL-1 translation. Nature Cell Biol, 17(8), 1049–61.
- Velarde, M. C., Demaria, M., Melov, S., Campisi, J. (2015 Aug 18). Pleiotropic age-dependent effects of mitochondrial dysfunction on epidermal stem cells. Proc Natl Acad Sci USA, 112(33), 10407–12.
- Wiley, C. D., Velarde, M. C., Lecot, P., Liu, S., Sarnoski, E. A., Shirakawa, K., Lim, H., Davis, S., Ramanathan, A., Gerencser, A. A., Verdin, E., Campisi, J. (2015 Dec 10). Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab, 23(2), 303–14.
- Demaria, M., O’Leary,, M. N., Chang J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., Alston, S., Academia, E. C., Kilmarx, S., Valdovinos, A., Wang, B., de Bruin, A., Kennedy, B. K., Melov, S., Zhou, D., Sharpless, N. E., Muss, H., Campisi, J. (2017 Feb). Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov, 7(2), 165–176.